Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 6/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883216 | 0.82 | ADORA2B (0.37) | KHKPDE5ADRD1DRD5ADORA1 | |
| SCHEMBL5884070 | 0.80 | PDE5A (0.39) | KHKPDE5A | |
| SCHEMBL5884027 | 0.78 | ADORA1 (0.37) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5884084 | 0.78 | KHK (0.36) | KHKPDE5ADRD1DRD5ADORA1 | |
| SCHEMBL5883465 | 0.76 | PDE5A (0.47) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5884388 | 0.75 | PDE5A (0.46) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5884346 | 0.75 | PDE5A (0.46) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5883962 | 0.75 | PDE5A (0.46) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5883665 | 0.75 | PDE5A (0.46) | KHKPDE5AADORA1ADORA2AADORA2B | |
| SCHEMBL5884330 | 0.73 | PDE5A (0.40) | KHKPDE5AADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | KHK 2954/4885PDE5A 409/4885DRD1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.